Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gusacitinib - Asana BioSciences

Next Previous
Drug Profile

Gusacitinib - Asana BioSciences

Alternative Names: ASN-002

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asana BioSciences
  • Developer Asana BioSciences; Libertas Bio
  • Class Acetonitriles; Antineoplastics; Antirheumatics; Piperidines; Pyridazines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Chronic lymphocytic leukaemia; Dermatitis; Myelofibrosis; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • No development reported Eczema; Rheumatoid arthritis

Most Recent Events

  • 05 Feb 2026 No development reported - Phase-III for Eczema (PO)
  • 23 Jun 2025 Gusacitinib licensed to Sanofi worldwide
  • 02 Feb 2024 National Institute of Arthritis and Musculoskeletal and Skin Diseases plans a phase I in Systemic lupus erythematosus in USA (PO, Tablet) in February 2024 (NCT06238531)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top